Name | Tirofiban |
Synonyms | C07965 MK-383 MK383 CS-584 L700462 Tirofiban Aggrastat TIROFIBAN AGGRASTAT N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine N-(butylsulfonyl)-O-[4-(piperidin-4-yl)butyl]-L-tyrosine (2s)-2-(butylsulfonylamino)-3-[4-[4-(4-piperidyl)butoxy]phenyl]propanoic acid |
CAS | 144494-65-5 |
EINECS | 635-682-4 |
InChI | InChI=1/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1 |
Molecular Formula | C22H36N2O5S |
Molar Mass | 440.6 |
Density | 1.154±0.06 g/cm3(Predicted) |
Melting Point | 223-225° |
Boling Point | 611.7±65.0 °C(Predicted) |
Flash Point | 323.7°C |
Vapor Presure | 8.09E-16mmHg at 25°C |
BRN | 6182267 |
pKa | 3.37±0.10(Predicted) |
Storage Condition | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
Refractive Index | 1.531 |
Physical and Chemical Properties | White solid, melting point 223~225 ℃. Tilofeba hydrochloride (Tirofiban Hydrochloride):C22H36N2O5S?HCl?H2O. [150915-40-5]. Solid, melting point 131~132 ℃. [α] D23-14.4 (C = 0.92, methanol). |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
RTECS | YP2364100 |
Reference Show more | 1. [IF=20.722] Huijuan Zhang et al."Shear force responsive and fixed-point separated system for targeted treatment of arterial thrombus."Nano Today. 2021 Jun;38:101186 |
white solid, melting point 223-225 °c.
L-tyrosine, acetonitrile and N,O-bis (trimethylsilyl) trifluoromethylacetamide were mixed, refluxed, and pyridine and N-butylsulfonyl chloride were added. After completion of the reaction, N-N-butylsulfonyl-L-tyrosine was obtained by treatment. Tetrahydrofuran was mixed with 4-methylpyridine, and a solution of N-butyllithium in hexane was slowly added, which was then slowly added to a solution of 3-bromo-1-chloropropane in tetrahydrofuran. After completion of the reaction, 4-(4-pyridyl) butyl chloride hydrochloride was obtained. N-N-butylsulfonyl-l-tyrosine and 4-(4-pyridyl) butyl chloride hydrochloride obtained above were dissolved in dimethyl sulfoxide, and an aqueous solution of potassium hydroxide was added with vigorous stirring, further reaction with the addition of potassium iodide gives N-(N-butylsulfonyl)-O-[4-(4-pyridyl) butyl]-L-tyrosine. This and the Palladium-on-carbon catalyst were dissolved in acetic acid, and after hydrogenation, tirofiban was worked up. In isopropyl acetate, acidification with concentrated hydrochloric acid gave tirofiban hydrochloride.
developed by Merck, USA, was first launched in the United States in 1998. Antithrombotic drugs. For the treatment of unstable angina. Specific non-peptide platelet fibrinogen receptor antagonists.